Malignant Neoplasm of Breast: A High-Yield USMLE Review

Breast cancer is a malignant epithelial tumor most commonly of ductal origin (invasive ductal carcinoma, no special type). It is a favorite USMLE vehicle for teaching the difference between grade (microscopic cell appearance) and stage (anatomic extent), and for illustrating how biomarkers — ER, PR, HER2, and Ki-67 — simultaneously forecast prognosis and predict which therapies will work.

Presentation

• Screen-detected breast mass on mammography — e.g., a 3 cm mass with a highly suspicious BI-RADS score prompting core needle biopsy
• Often no symptoms and no family history — many cases are found on routine screening rather than by complaint
• Family-history clustering: a first-degree relative with premenopausal breast cancer raises risk and shifts screening earlier/more intensively
• Late/long-term sequelae of treatment — a remote history of lumpectomy and radiation can produce delayed radiation-induced cardiotoxicity (valvular or pericardial disease)

Diagnosis

• Screening mammography detects the mass and stratifies suspicion by BI-RADS score (a score of 5 is highly suspicious)
• Core needle biopsy with histopathology confirms invasive ductal carcinoma and assigns Nottingham grade (tubule formation, nuclear pleomorphism, mitotic count)
• Immunohistochemistry for ER, PR, HER2, and Ki-67 — a 3+ HER2 IHC (strong complete membrane staining in >10% of cells) is strongly positive without reflex FISH
• Anatomic staging (TNM: tumor size, regional nodes, distant metastases) determines curability independent of grade

Management

• Surgical resection is the backbone for localized disease (e.g., lumpectomy with sentinel node biopsy), with radiation as appropriate
• Adjuvant systemic therapy is added based on biology: high grade or aggressive biomarkers signal aggressiveness even at low stage and push toward adjuvant therapy
• HER2-directed targeted therapy for HER2-positive tumors — trastuzumab (anti-HER2 antibody), pertuzumab (blocks dimerization), and ado-trastuzumab emtansine (antibody–drug conjugate)
• Endocrine therapy with tamoxifen for ER-positive disease — avoid strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion), which reduce conversion to active endoxifen
• Patient selection matters: in patients whose competing life expectancy is short (e.g., end-stage comorbidity), forgo surgery even when technically feasible

High-yield

• Grade is microscopic (Nottingham for breast); stage is anatomic (TNM) — stage is the dominant prognostic factor and determines curability, while grade modifies treatment intensity within stage
• HER2 positivity is both prognostic (worse natural history untreated) and predictive (responds to trastuzumab) — the net survival effect flipped from negative to positive once trastuzumab entered practice
• HER2 is over-expressed in about 15–20% of breast cancers
• A grade 3, ER-negative, PR-negative, HER2-positive, high-Ki-67 tumor is biologically aggressive yet has a targetable driver
• BRCA1 mutation carries roughly 60–70% penetrance for breast cancer by age 70; a first-degree relative with premenopausal disease is a trigger for genetic counseling
• 2024 USPSTF: biennial screening mammography ages 40–74; above 74 is shared decision-making with insufficient evidence

Pitfalls

• Conflating grade with stage — the most common Step 1 trap. A high-grade Stage I cancer is often curable with surgery alone; a low-grade Stage IV cancer usually is not.
• Assuming high grade reverses prognosis or curability — grade modifies adjuvant treatment intensity, but stage drives whether the disease is curable
• Prescribing a strong CYP2D6 inhibitor (fluoxetine, paroxetine, bupropion) to a woman on tamoxifen, reducing endoxifen and efficacy
• Substituting 'can' for 'should' — offering surgery to a patient whose competing life expectancy is shorter than the cancer's natural history
• Reflexively acting on EHR screening alerts in elderly/frail patients without asking whether a screen-detected cancer would change management within her life expectancy